Silencing cyclin-dependent kinase inhibitor 3 inhibits the migration of breast cancer cell lines.

Cyclin-dependent kinase inhibitor 3 (CDKN3) belongs to the dual-specificity protein phosphatase family, which is hypothesized to regulate cell cycle progression in tumor cells. However, whether CDKN3 is a potential therapeutic target for breast cancer remains to be elucidated. The present in vitro study aimed to investigate the potential roles of CDKN3 in breast cancer.

Lymph node ratio and breast cancer prognosis: a meta-analysis.

Due to the heterogeneity of lymph node examination and the conflicting results existing for the same classification of lymph node ratio (LNR), it is necessary to conduct a meta-analysis to evaluate the prognostic effects of different LNRs on breast cancer. PubMed, EMBASE, and ISI Web of Knowledge were searched to find all published cohort studies that evaluated the prognostic value of different LNRs on breast cancer. The outcomes were overall survival (OS), disease-free survival (DFS), breast cause-special survival (BCCS), mortality, locoregional recurrence (LRR), and distant metastasis.

Micellar nanoparticles loaded with gemcitabine and doxorubicin showed synergistic effect.

Gemcitabine and doxorubicin were separately chemically linked to biodegradable polymers to prepare polymer-gemcitabine and polymer-doxorubicin conjugates. Moreover, the two conjugates can self-assemble into micelles with both gemcitabine and doxorubicin. In this way, the two anticancer drugs were combined.